City Therapeutics (CTY) closed at $22.40 on October 16, 2026, on volume of 1,332,974 shares.
Data as of October 16, 2026.
No press releases found.
RNAi drug developer City climbs after upsized IPO
Seeking Alpha News (Fri, 16-Oct 1:24 PM ET)
RNAi drugmaker City prices upsized IPO at $18 per share
Seeking Alpha News (Fri, 16-Oct 9:51 AM ET)
City Therapeutics Inc is a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics designed to silence the expression of disease-relevant proteins. Its current pipeline is focused on indications with unmet medical need, including thromboembolic diseases, Stargardt disease type 1 (Stargardt disease), and anemia of chronic disease.
City Therapeutics trades on the NASDAQ stock market under the symbol CTY.
As of October 16, 2026, CTY stock price climbed to $22.40 with 1,332,974 million shares trading.
CTY has a market cap of $1.08 billion. This is considered a Small Cap stock.
